Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Part of paid clinical trials in Stanford, California.

Sponsor
Exelixis
Study ID
NCT01683110
Status
Approved For Marketing

Conditions

  • Medullary Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.

Key Dates

Status verified
Jan 2013

Locations (5)

FacilityCityStateZIPSite coordinators
-StanfordCalifornia94305-
-BostonMassachusetts02114-
-DetroitMichigan48202-
-PortlandOregon97239-
-PhiladelphiaPennsylvania19104-

Related Studies